Maze Therapeutics (NASDAQ:MAZE) Given New $51.00 Price Target at JPMorgan Chase & Co.

Key Points

• JPMorgan cut its Maze Therapeutics price target to $51 from $53 but maintained an “overweight” rating; the new target implies about 37.5% upside from the cited share price.
• Analyst sentiment remains broadly positive: MarketBeat reports a consensus “Buy” rating and an average price target of $63.91, with ratings ranging from Strong Buy to Sell.
• Maze reported quarterly EPS of -$0.79, slightly below analysts’ -$0.78 estimate. Insiders also sold a combined 192,991 shares worth about $5.2 million over the past 90 days.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) had its price objective decreased by equities research analysts at JPMorgan Chase & Co. from $53.00 to $51.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm currently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s price target points to a potential upside of 37.52% from the stock's current price.

A number of other research analysts also recently issued reports on the stock. Canaccord Genuity Group started coverage on shares of Maze Therapeutics in a research report on Monday, October 19th. They set a "buy" rating and a $75.00 price objective on the stock. Wedbush lifted their price target on Maze Therapeutics from $48.00 to $49.00 and gave the company an "outperform" rating in a research report on Tuesday. BTIG Research restated a "buy" rating and issued a $46.00 price objective on shares of Maze Therapeutics in a report on Tuesday, September 22nd. HC Wainwright restated a "buy" rating and set a $110.00 price target on shares of Maze Therapeutics in a report on Thursday, September 24th. Finally, Citigroup started coverage on shares of Maze Therapeutics in a research report on Wednesday, September 23rd. They set a "buy" rating and a $50.00 price target for the company. Three equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $63.91.

Maze Therapeutics Trading Up 4.6%

MAZE traded up $1.64 during midday trading on Wednesday, reaching $37.09. 122,243 shares of the company's stock traded hands, compared to its average volume of 671,773. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 18.31. Maze Therapeutics has a 52 week low of $21.95 and a 52 week high of $53.65. The stock has a market capitalization of $2.06 billion, a price-to-earnings ratio of -14.02 and a beta of 2.04. The firm has a fifty day moving average of $28.12 and a two-hundred day moving average of $31.67.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its earnings results on Monday, November 9th. The company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.78) by ($0.01). On average, equities analysts anticipate that Maze Therapeutics will post -2.70 earnings per share for the current fiscal year.

Insider Buying and Selling at Maze Therapeutics

In other news, CMO Harold Bernstein sold 16,142 shares of the firm's stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $27.61, for a total transaction of $445,680.62. Following the sale, the chief marketing officer owned 16,142 shares of the company's stock, valued at $445,680.62. This trade represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of Maze Therapeutics stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $27.58, for a total transaction of $206,850.00. Following the completion of the sale, the insider owned 26,250 shares of the company's stock, valued at $723,975. This represents a 22.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 192,991 shares of company stock worth $5,187,559. Company insiders own 5.30% of the company's stock.

Institutional Investors Weigh In On Maze Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Bessemer Group Inc. boosted its stake in shares of Maze Therapeutics by 3.0% in the 3rd quarter. Bessemer Group Inc. now owns 496,253 shares of the company's stock worth $13,488,000 after buying an additional 14,463 shares during the last quarter. Jefferies Financial Group Inc. purchased a new stake in Maze Therapeutics during the third quarter valued at $1,519,000. Alps Advisors Inc. lifted its holdings in Maze Therapeutics by 31.5% in the third quarter. Alps Advisors Inc. now owns 73,574 shares of the company's stock valued at $2,000,000 after acquiring an additional 17,604 shares during the period. Mirae Asset Global Investments Co. Ltd. bought a new position in Maze Therapeutics in the third quarter valued at about $77,000. Finally, Profund Advisors LLC boosted its position in Maze Therapeutics by 410.5% in the third quarter. Profund Advisors LLC now owns 56,281 shares of the company's stock worth $1,530,000 after purchasing an additional 45,256 shares during the last quarter.

Maze Therapeutics Company Profile

Maze Therapeutics is a clinical-stage biotechnology company developing precision medicines for people with serious diseases. Its research uses human genetics and functional genomics to identify disease-related biological pathways and potential drug targets. The company's Maze Compass platform is designed to connect genetic insights with biological research to guide drug discovery and development. Its investigational programs have included approaches for APOL1-mediated kidney disease and Pompe disease; these are not marketed treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.